MONTREAL--(EON: Enhanced Online News)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that an abstract on its Angiopep-2 (An2) conjugate technology has been selected for presentation at the American Society of Human Genetics (ASHG) 2013 Annual Meeting being held October 22-26, 2013 in Boston, Massachusetts.
“These data demonstrate the ability of Angiochem technology to create proteins that can access the CNS; a key attribute for enzyme replacement therapy”
“These data demonstrate the ability of Angiochem technology to create proteins that can access the CNS; a key attribute for enzyme replacement therapy,” commented Jean E. Lachowicz, Ph.D., Chief Scientific Officer of Angiochem Inc. “We are applying this approach to an enzyme associated with mucopolysaccharidosis to create a brain-penetrant enzyme replacement therapy that will address neurological symptoms.”
(Abstract/Poster #2288F): Friday, October 25, 2013, 11:30-12:30 p.m. ET, “Fusion with Angiopep-2 to create proteins that cross the blood-brain barrier and are taken up into cells,” Jean E. Lachowicz, Ph.D., Therapy for Genetic Disorders Session, Convention Center, Exhibit Hall, Level 1.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.